-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The clinical prognosis of myelofibrosis patients with relapse or JAKi refractory (R/R) after treatment with Janus-related kinase inhibitor (JAKi) is poor, and the overall survival rate (OS) is only 13-16 months
Imetelstat is a telomerase inhibitor Imetelstat is a telomerase inhibitor
The test patients were randomly divided into groups and received Imetelstat 9.
A: OS of all randomized patients; B: correlation between OS and myelofibrosis change or stability
A: OS of all randomized patients; B: correlation between OS and myelofibrosis change or stabilityStudy enrollment ended early, and patients receiving 4.
At 24 weeks, the spleen remission rate and symptom remission rate were 10.
All in all, in this phase II trial of two doses of Imetelstat, patients with bad-risk JAKi-R/R myelofibrosis can get clinically beneficial symptoms from Imetelstat 9.
JAKi-R/R myelofibrosis patients with adverse risks can obtain clinically beneficial symptom relief from Imetelstat 9.
Original source:
John Mascarenhas, et al.
Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis
in this message